🔎 Trials Near Me

Utama › Limfoma Burkitt › Arkansas

Kajian klinikal Limfoma Burkitt di Arkansas

5 kajian untuk Limfoma Burkitt sedang mencari peserta di lokasi di Arkansas.

Bandar di Arkansas

Teks kajian rasmi (Bahasa Inggeris)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 2
366 Days – 46 Years · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 2
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 3
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

  • Arkansas Children's, Little Rock
  • Arkansas Children's Northwest, Springdale
Mengambil pesertaKajian pemerhatian
Umur 1 hingga 23 · Semua jantina · Dikemas kini 25 Feb 2026 · NCT07422337

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.